Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AHA: Magnesium Shows Promise for Thrombolysis-ineligible Cardiac Patients By Jill Stein Special to DG News ANAHEIM, CA -- November 14, 2001 -- New data identify a possible role for magnesium supplementation in acute myocardial infarction (MI) patients who are not suitable candidates for thrombolytic therapy. The results, based on a long-term follow-up of thrombolysis-ineligible patients who were treated with magnesium supplements, were reported yesterday (Nov. 13) at the annual meeting of the American Heart Association (AHA), in Anaheim, California. An earlier prospective, double-blind, placebo-controlled trial found that a 22 g infusion of intravenous magnesium sulfate given over 48 hours to 194 consecutive acute MI patients who were deemed ineligible for thrombolysis significantly decreased the in-hospital mortality rate from 7 percent to 2 percent compared to isotonic glucose as placebo. Dr. Michael Schechter at the Sheba Medical Center, in Tel Aviv, Israel, and co-workers, who conducted the earlier investigation, decided to evaluate the long-term survival and cardiac function of the same study population. Patients received 22 g of magnesium sulfate dissolved in 500 mL of isotonic glucose, or 500 mL of isotonic glucose as placebo during the first 48 hours. All patients who survived the last year of follow-up underwent rest radionuclide ventriculography tests for left ventricular (LV) ejection fraction, conducted by a cardiologist blinded to the study medication and to patients’ clinical course. The two groups were matched for baseline risk factors, infarct location, and in-hospital and long-term therapy. Results showed that all-cause and cardiac 4.8-year mortality rates were significantly lower in the magnesium compared to the placebo group (18 versus 33 patients and 12 versus 30 patients). After 8.7 years, 70 (38 percent) of 183 patients died; 32 (36 percent) receiving magnesium and 38 (41 percent) receiving placebo. Cardiac death was diagnosed in 55 patients (22 magnesium and 33 placebo patients) and non-cardiac death in 15 patients (10 magnesium and five placebo patients). Dr. Schechter said the data suggest that the beneficial effects of intravenous magnesium therapy appear to last at least 8.7 years after acute treatment, concomitant with preserved left ventricular ejection fraction. E-mail this page to a friend or colleague! To print, use this version